| Characteristics | Statistics, n (%) |
| N | 14 |
| Age at infusion (years) | |
| Mean (SD) | 66.9 (8.1) |
| Median (range) | 66 (51–78) |
| Gender | |
| Male | 12 (85) |
| Female | 2 (14) |
| No. of previous therapies | |
| Mean (SD) | 5.3 (2.8) |
| Median (range) | 5 (1–11) |
| P53 or 17p deletion | |
| No | 8 (57) |
| Yes | 6 (43) |
| IGHV mutation | |
| No | 9 (64) |
| Yes | 4 (29) |
| Unknown | 1 (7) |
| Lymphocyte-depleting chemotherapy | |
| Bendamustine | 6 (43) |
| Fludarabine/cyclophosphamide | 3 (21) |
| Pentostatin/cyclophosphamide | 5 (36) |
| Lymphocytes in bone marrow at enrollment (%)* | |
| Mean (SD) | 79.5 (17.9) |
| Median (range) | 87.5 (40–95) |
| Rai stage | |
| 1 | 5 (36) |
| 4 | 9 (64) |
| Binet stage | |
| A | 1 (7) |
| B | 4 (29) |
| C | 9 (64) |
*Data not available for four subjects.